Evaluating a Blood Test for Lung Cancer
Author Information
Author(s): E.H. Cooper, T.A.W. Splinter, D.A. Brown, M.F. Muers, M.D. Peake, S.L. Pearson
Primary Institution: Unit for Cancer Research, University of Leeds
Hypothesis
Can neuron specific enolase (NSE) levels in the blood be used to monitor small cell lung cancer (SCLC) effectively?
Conclusion
The study found that serum NSE levels are a valuable marker for monitoring SCLC during and after chemotherapy.
Supporting Evidence
- 68% of untreated patients with localized SCLC had raised NSE levels.
- 87% of patients with extensive SCLC had raised NSE levels.
- Only 17% of patients with non-small cell lung cancer had raised NSE levels.
Takeaway
Doctors can check a special protein in the blood to see how well treatment is working for a type of lung cancer called small cell lung cancer.
Methodology
The study involved measuring NSE levels in blood samples from 171 lung cancer patients, including 77 with SCLC and 94 with non-small cell lung cancer (NSCLC), before treatment and during follow-up.
Limitations
The study may not account for all types of lung cancer and the results may vary based on individual patient factors.
Participant Demographics
Patients included 77 with small cell lung cancer and 94 with non-small cell lung cancer, with various histological types.
Want to read the original?
Access the complete publication on the publisher's website